Jane Street’s Apogee Therapeutics APGE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.92M Sell
29,500
-26,300
-47% -$2.37M ﹤0.01% 4076
2026
Q1
$4.7M Buy
55,800
+50,100
+879% +$3.64M ﹤0.01% 3618
2025
Q4
$430K Sell
5,700
-29,800
-84% -$1.88M ﹤0.01% 8042
2025
Q3
$1.41M Sell
35,500
-300
-0.8% -$11.5K ﹤0.01% 5592
2025
Q2
$1.55M Buy
35,800
+25,900
+262% +$985K ﹤0.01% 4828
2025
Q1
$370K Sell
9,900
-5,300
-35% -$205K ﹤0.01% 7450
2024
Q4
$689K Sell
15,200
-34,800
-70% -$1.77M ﹤0.01% 6100
2024
Q3
$2.94M Buy
+50,000
New +$2.4M ﹤0.01% 3752

Other funds holding APGE

Jane Street's APGE Position: Q2 2026 in Review

Jane Street opened a new position in Apogee Therapeutics (APGE) in Q2 2026: 3,245 shares worth $431K. The stake represents ﹤0.01% of the portfolio and ranks #8381 among its holdings. This is a return to the name: Jane Street previously reported a position in APGE as recently as Q4 2025.

Jane Street first reported a position in APGE in Q3 2023 and has held it in 11 quarters since. The position peaked at $3.73M in Q1 2024. 289 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • Jane Street held 3,245 shares of Apogee Therapeutics worth $431K as of Q2 2026.
  • Apogee Therapeutics was a new Jane Street position in Q2 2026.
  • Apogee Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q2 2026, its #8381 holding.
  • Jane Street first reported a position in Apogee Therapeutics in Q3 2023 and has held it in 11 quarters since.
  • Jane Street's Apogee Therapeutics position peaked at $3.73M in Q1 2024.
  • 289 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.